Can I Take Alpha-Lipoic Acid with Finasteride?

What Is the Actual Interaction Between ALA and Finasteride?

The two substances do not share a metabolic pathway that creates a classic pharmacokinetic drug-drug interaction. Finasteride is metabolized primarily by CYP3A4 [1], and ALA does not meaningfully inhibit or induce that enzyme at doses up to 1,200 mg/day. The concerns are pharmacodynamic: ALA acts on insulin signaling and thyroid hormone binding independently of finasteride, and those effects can matter depending on your health status.

Pharmacokinetics: Why the Pathways Do Not Collide

Finasteride reaches peak plasma concentration roughly 1 to 2 hours after an oral dose and has a half-life of 5 to 6 hours in younger men and up to 8 hours in men over 70 [1]. Protein binding is approximately 90%. ALA, by contrast, is absorbed rapidly, reaches peak plasma levels within 30 to 60 minutes of an oral dose, and is largely gone from plasma within 4 hours [2]. Neither compound alters the other's absorption, distribution, metabolism, or elimination in a clinically documented way.

Pharmacodynamics: Where the Real Concerns Live

ALA is an endogenous dithiol antioxidant that activates insulin receptor substrate-1 (IRS-1) signaling and GLUT4 translocation, effectively mimicking some of insulin's glucose-lowering actions [3]. A 2011 meta-analysis of four randomized controlled trials (total N=311) found that oral ALA supplementation reduced fasting glucose by a mean of 2.7 mg/dL and fasting insulin by 1.77 µIU/mL in patients with metabolic syndrome [4]. In a healthy, non-diabetic male using finasteride for androgenetic alopecia, that degree of glucose reduction is unlikely to cause symptoms. For a man with type 2 diabetes already on metformin or a sulfonylurea, the additive effect could push glucose lower than intended.

Finasteride itself does not directly alter insulin sensitivity, so the glucose concern originates entirely from ALA, not from the combination per se.

Does ALA Affect Thyroid Hormones When Combined with Finasteride?

Finasteride has no documented effect on thyroid hormone levels [1]. ALA does. This section matters because some men on finasteride also experience changes in androgen-to-estrogen balance, and thyroid function is a common co-concern in men investigating hair loss.

ALA and T4: What the Data Show

A randomized, double-blind trial published in the European Journal of Endocrinology (N=58 Hashimoto's thyroiditis patients) found that 600 mg/day of ALA taken for 3 months reduced free T4 by approximately 12% compared with placebo [5]. The proposed mechanism is competitive binding to transthyretin (TTR), the serum transport protein that carries T4, because ALA structurally resembles thyroxine's side chain [5].

A separate observational study in euthyroid adults taking ALA at 1,200 mg/day for weight loss reported a mean free T4 reduction of 16 to 20%, with TSH rising slightly but remaining within the reference range in most subjects [6]. The authors noted that the effect was dose-dependent and largely reversed four weeks after stopping ALA.

What This Means for Finasteride Users

Finasteride does not protect against ALA's thyroid effect, nor does it amplify it. Men with subclinical hypothyroidism, a TSH already trending toward 4.0 mIU/L, or those on levothyroxine should inform their prescriber before starting ALA above 600 mg/day. Standard ALA doses for neuroprotection or antioxidant purposes (300 to 600 mg/day) are less likely to produce a clinically meaningful T4 shift based on the dose-response pattern in the available data.

How Does ALA's Antioxidant Action Relate to Hair Loss?

This is a common question because both finasteride and ALA are used in hair-health contexts, though through entirely different mechanisms. Finasteride blocks 5-alpha reductase type II, reducing scalp dihydrotestosterone (DHT) by approximately 60 to 70% at the 1 mg dose [7]. That hormonal reduction addresses the primary driver of androgenetic alopecia.

ALA's Role in Oxidative Stress and the Follicle

Oxidative stress is a contributing factor in hair follicle miniaturization. A 2020 review in the Journal of Cosmetic Dermatology summarized evidence that reactive oxygen species accelerate follicle cycling and promote early catagen transition [8]. ALA, as a cofactor for mitochondrial dehydrogenase complexes and a recycler of glutathione and vitamins C and E, theoretically reduces that oxidative burden [2]. No large randomized controlled trial has confirmed that oral ALA monotherapy regrows hair in androgenetic alopecia. The evidence base for ALA in hair loss remains preliminary, drawn largely from in vitro and small open-label studies.

Combining Mechanisms: Additive or Redundant?

Because finasteride targets the androgen axis and ALA targets oxidative stress, the two mechanisms are distinct rather than redundant. Some clinicians describe this as complementary. Whether the oxidative-stress component of androgenetic alopecia is large enough that reducing it produces measurable clinical benefit on top of DHT suppression is not yet established by head-to-head trial data.

The HealthRX clinical team uses the following three-tier framework when evaluating supplement co-administration with finasteride:

Tier 1 (No concern): Supplements with no shared metabolic pathway and no pharmacodynamic overlap with finasteride's 5-AR mechanism. ALA falls here for most healthy men.

Tier 2 (Monitor): Supplements that alter glucose, thyroid hormones, or androgen metabolism independently of finasteride. ALA moves into Tier 2 for men with diabetes, pre-diabetes, or thyroid disease.

Tier 3 (Avoid or seek prescriber guidance first): Supplements that directly inhibit or induce CYP3A4 (e.g., St. John's Wort at high doses) or that alter DHT measurement, making it harder to assess finasteride's efficacy.

ALA sits at Tier 1 for a healthy adult male and at Tier 2 for those with metabolic or thyroid comorbidities.

Blood Glucose Monitoring: Who Needs It and How Often?

The FDA label for finasteride does not list hypoglycemia as an adverse effect [1]. ALA's glucose-lowering potential, while modest in healthy subjects, is documented in clinical trial settings [3][4].

Identifying Your Risk Category

Men with fasting glucose below 100 mg/dL, no diabetes diagnosis, and no insulin or secretagogue use have a low probability of experiencing symptomatic hypoglycemia on ALA 300 to 600 mg/day. Symptoms of mild hypoglycemia (shakiness, sweating, palpitations) typically appear at blood glucose below 70 mg/dL in adults.

Men on metformin alone have a low but non-zero risk because metformin by itself rarely causes hypoglycemia. Men on a sulfonylurea (glipizide, glyburide, glimepiride), insulin, or an SGLT2 inhibitor should discuss the addition of ALA with their prescriber before starting, because additive glucose reduction at those baseline regimens is more likely to produce symptoms.

Practical Monitoring Steps

A fasting glucose check at baseline, at 4 weeks, and at 12 weeks after starting ALA is reasonable for anyone with pre-diabetes (fasting glucose 100 to 125 mg/dL). Self-monitoring before and after the first week of ALA use at a new dose provides early reassurance. The American Diabetes Association's Standards of Care recommend that any supplement with documented insulin-sensitizing activity be recorded in the medication reconciliation list [9].

Thyroid Monitoring: When to Check TSH and Free T4

Men using finasteride who are otherwise healthy and euthyroid do not routinely need thyroid labs just because they are adding ALA at 300 to 600 mg/day. The data showing meaningful T4 reduction came from higher doses (600 to 1,200 mg/day) and from patients with pre-existing autoimmune thyroid disease [5][6].

Higher-Risk Scenarios

A man with known Hashimoto's thyroiditis who adds ALA 600 mg/day should have TSH and free T4 checked at baseline and again at 3 months, particularly if he is on levothyroxine, because even a modest reduction in free T4 could push him into symptomatic hypothyroidism territory. The American Thyroid Association's guidelines on thyroid hormone therapy note that a target TSH of 0.5 to 2.5 mIU/L is appropriate for most levothyroxine users, leaving limited buffer for a 10 to 15% free T4 reduction [10].

Dose Threshold to Keep in Mind

Available evidence suggests that ALA doses at or below 300 mg/day produce minimal thyroid signal. The 600 mg/day dose produced approximately 12% free T4 reduction in the Hashimoto's trial [5]. Scaling above 600 mg/day (sometimes used for diabetic neuropathy) carries a higher likelihood of detectable thyroid change. Men without thyroid disease who stay at 300 to 600 mg/day are unlikely to need extra lab monitoring solely for thyroid function.

Safe Co-Administration: Practical Guidance

Taking ALA with food slows its absorption slightly but also reduces the chance of gastrointestinal discomfort, which is the most commonly reported adverse effect of oral ALA at 600 mg/day (reported in roughly 6% of subjects in the SYDNEY 2 trial, N=181) [11]. Finasteride can be taken with or without food at any time of day [1]. There is no pharmacokinetic reason to separate the two doses by a specific window.

Suggested Daily Schedule

Morning with breakfast: ALA 300 to 600 mg, finasteride 1 mg (or 5 mg for BPH). This timing consolidates pill burden and links ALA's glucose effect to a meal, reducing any hypoglycemic nadir.

What to Tell Your Prescriber

Inform your prescriber that you are taking ALA, your dose, and the brand formulation (R-ALA versus racemic ALA). The R-enantiomer is more bioavailable and produces stronger metabolic effects at the same nominal dose [2]. A prescriber who knows you are on R-ALA 600 mg/day (equivalent in effect to roughly 1,200 mg racemic) may make a different monitoring decision than one who assumes a standard 300 mg racemic capsule.

Signs That Warrant a Check-In

If you notice unusual fatigue, cold intolerance, unexplained weight gain, or brain fog after starting ALA, those symptoms could reflect a subclinical hypothyroid shift and are worth reporting. Shakiness, sweating, or lightheadedness in a fasted state could indicate glucose running lower than expected.

What the Research Does Not Yet Tell Us

No randomized controlled trial has examined the combined use of finasteride and ALA as a co-intervention. The interaction literature for ALA relies heavily on studies in diabetic neuropathy populations [11], metabolic syndrome cohorts [4], and autoimmune thyroid disease patients [5], none of whom are the typical finasteride user (a healthy male in his 20s to 50s with androgenetic alopecia).

Extrapolating from those populations to a healthy man is reasonable but involves uncertainty. The absence of a documented pharmacokinetic interaction is reassuring. The pharmacodynamic concerns described above are real but context-dependent, applying mainly to men with co-existing metabolic or thyroid conditions.

The SYDNEY 2 trial, the largest randomized placebo-controlled trial of high-dose ALA in diabetic polyneuropathy (N=181, 600 mg/day for 5 weeks), reported a 51% improvement in Total Symptom Score versus 32% with placebo (P<0.001) and documented a safety profile that did not include serious cardiovascular or hormonal adverse events [11]. That safety signal, while from a different indication, supports ALA's tolerability at therapeutic doses.